Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (149)	4/9/1999 2:16:00 PM
From: scaram(o)uche	Respond to of 52153

>> SUGN is going to need some time to get over the 60 minutes extravaganza, and CELG probably needs to start showing some real sales of Thalomid before it moves. Both good stocks to be patient with. << BTW, Mike.... I agree with Peter here. However, CELG is also a leveraged business plan. They have unpartnered projects that are of great interest, significant interest. In addition, they are better positioned than any company that I can think of to profit from potential deregulation at FDA. More multiple myeloma results for thalidomide will be presented at ASCO. This business plan could come together, suddenly.

To: Biomaven who wrote (149)	4/11/1999 2:49:00 PM
From: LLCF	Read Replies (1) \| Respond to of 52153

<They do have an anti-angiogenesis candidate> Front page Chicago Tribune, main article... pictures, the whole shot, about Folkman, angio/endo statin. Nothing new, just what has happened up till now. Trials to start this year (forth quarter) at Wisconsin-Madison, and in Texas. Northwestern Dr. Gerald Soff believes he has found a more efficient method of producing angiostatin. Mentions that the 2 trials are Entremed trials. Mostly a "Folkman piece". DAK